CNK1 inhibitors represent a class of small molecules designed to modulate the cellular signaling pathways associated with CNK1, also known as Connector Enhancer of Kinase Suppressor of Ras 1. CNK1 is a scaffolding protein that plays a pivotal role in orchestrating signal transduction events by bringing together various components of signaling cascades, thereby facilitating efficient and specific cellular responses. The development of CNK1 inhibitors stems from a deeper understanding of its involvement in intricate intracellular networks, particularly those linked to growth factor receptor activation, MAP kinase signaling, and cell proliferation. These inhibitors function by specifically targeting CNK1-related signaling pathways and disrupting their propagation. The molecular mechanisms through which CNK1 inhibitors exert their effects are diverse, ranging from interference with key protein-protein interactions to inhibition of downstream effectors within the signaling cascade.
The primary objective of these inhibitors is to impede the assembly of CNK1-associated signaling complexes, which subsequently hinders the proper transmission of signals that are crucial for cellular processes. By blocking CNK1's ability to scaffold and coordinate various components of signaling pathways, these inhibitors essentially act as molecular "breaks" that impede the uncontrolled or aberrant activation of downstream targets.
Researchers have identified various chemical scaffolds and structural features that contribute to the potency and selectivity of CNK1 inhibitors. These molecules are often designed to bind to specific regions of CNK1 or its interacting partners, impeding the formation of active signaling complexes. As our understanding of CNK1's role in different cellular contexts grows, the design and optimization of CNK1 inhibitors continue to evolve, with the aim of discovering more potent and specific compounds. While these inhibitors have been developed as valuable tools to dissect signaling pathways in research settings, their implications and broader applications are still subjects of ongoing investigation and experimentation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits CNK1 by disrupting Raf-MEK-ERK signaling pathway. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Blocks CNK1-related pathways by inhibiting EGFR and HER2. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits CNK1 by targeting tyrosine kinases, particularly BCR-ABL. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Interferes with CNK1 signaling pathways via VEGFR and PDGFR inhibition. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Disrupts CNK1-related pathways by inhibiting multiple tyrosine kinases. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Inhibits CNK1-involved signaling through EGFR tyrosine kinase inhibition. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Targets MEK and downstream CNK1-associated pathways. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Blocks CNK1 by inhibiting BCR-ABL and other tyrosine kinases. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Interferes with CNK1 pathways by inhibiting VEGFR and PDGFR. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits CNK1-associated signaling by targeting VEGFR and EGFR. | ||||||